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Objectives/Hypothesis: Microbial biofilms have been implicated in the pathogenesis of chronic rhinosinusitis with nasal
polyposis (CRSwNP). Although biofilms are characterized by an extremely high resistance against chemical and physical
agents, low-frequency ultrasound (LFU) treatment has been suspected to be an efficient and safe method for biofilm
disruption.
Study Design: Basic science experimental study.
Methods: A total of 10 patients with CRSwNP undergoing endoscopic sinus surgery were analyzed. Two series of
identical nasal polyps (n ¼ 20) were processed to hematoxylin-eosin (HE) and Gram staining and to continuous-wave LFU
treatment (5 minutes, 0.4 MHz, 37C), respectively.
Results: Presence of microbial biofilms was confirmed in all patients with CRSwNP. HE staining showed a strong corre-
lation with the results of Gram protocol in biofilm detection. In the LFU-treated group (n ¼ 10), a significantly decreased
inflammatory cell count was found in the subepithelial layer of nasal polyps (P < .001). In addition, bacterial biofilms were
completely removed from the surface of the epithelial layer. Microscopic tissue injuries or significant temperature changes
were not detected due to LFU treatment.
Conclusions: Between in vitro conditions, LFU treatment appeared to be a reliable and microscopically safe method for
the disruption of microbial biofilms in CRSwNP. These results may provide a basis for a prospective human study investigat-
ing the efficacy and safety of this therapeutic modality alone or in combination with antibiotics or topical steroids in biofilm-
positive cases of CRSwNP.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is a common inflam-
matory disease that is characterized by nasal
obstruction, olfactory dysfunction, nasal discharge, and
tension pain that persist over 3 months.1,2 CRS with
nasal polyposis (CRSwNP) is a distinct diagnostic and
therapeutic entity with unclarified etiopathogenesis.1,2
CRSwNP is currently considered as an immunological
disease that is affected by immunological disorders, envi-
ronmental factors, Staphylococcus superantigens, fungal
infections, and the presence of microbial biofilms.1–3
Biofilm creates a special environment for microbial
survival and proliferation that consists of a self-pro-
duced, three-dimensional extracellular matrix formed by
polysaccharides, proteins, nucleic acids, and water.4–6
Microbial biofilms are characterized by extremely high
resistance against antibiotics, host immune reactions,
and chemical and physical agents.3–5 This strong and
continuously remodeled physical barrier blocks the diffu-
sion of antibiotics, superoxides, immunoglobulins, and
opsonins.3,5,6 Biofilms and consecutive inflammatory
reactions might contribute to the epithelial damage and
subsequent hyperplasia of the subepithelial layer, result-
ing in nasal polyp formation.6–9 Persisting biofilms in
CRSwNP may be responsible for surgical failures and
high recurrence rate of disease.1,6,7 Because biofilms are
supposed to play an important role in the pathogenesis
of CRSwNP, several therapeutic protocols targeting
these structures have been reported and tested in recent
years.1,2,10
Long-term and low-dose macrolide antibiotic ther-
apy has been supposed to have therapeutic advantages
in the elimination of bacterial biofilms in CRSwNP.11,12
Beyond the bacteriostatic effects, macrolides have a
potential role in the modulation of immune response and
consecutive tissue reactions.12–14 However, there are
conflicting results. In the MACS study (Macrolides in
Chronic Rhinosinusitis), low-dose and long-term applica-
tion of azithromycin did not have any advantages
against placebo between clinical conditions.15 Because
microbial biofilms are characterized by strong negative
electrical charge, cationic detergents may have beneficial
effects in biofilm disruption.16 It has been reported that
1% baby shampoo has no effects on preformed biofilms;
however, it may prevent biofilm formation after endo-
scopic sinus surgery (ESS) of patients with CRSwNP.16
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In the light of these results, more research is required to
investigate the effectiveness of macrolide and cationic
detergent therapy against biofilms in CRSwNP.
There is increasing evidence that continuous- (CUS)
or pulsed-wave (PUS) low-frequency ultrasound (LFU)
treatment is a reliable and safe method for biofilm removal
in CRSwNP.10,17–19 Bartley and Young discussed that intra-
nasal application of therapeutic ultrasound may increase
the sensitivity against antibiotics due to the physical frag-
mentation of compact biofilm barriers.17 Preoperative
application of LFU treatment may increase the surgical
success rates with decreased frequency of repeated sur-
geries due to recurring disease.17 Young et al. treated 22
CRSwNP patients by 1 MHz pulsed-wave ultrasound 2 to 3
days a week for six sessions.18 In contrast to the extranasal
application of LFU treatment, the authors have reported a
significant improvement of sinusitis symptoms in 18
patients according to the decreased values of Sino-Nasal
Outcome Test questionnaire.18 Later, Ansari et al. reported
a significant difference between the effectiveness of pulsed-
wave (PUS) and continuous-wave (CUS) ultrasound ther-
apy in CRS.20 The authors found a greater improvement of
sinusitis-associated symptoms in the PUS-treated patient
group.20 In a preliminary study on cadaver heads, Patel
et al. demonstrated that LFU treatment is a safe protocol
that was confirmed by histopathological analysis of the
ultrasound-treated nasal mucosa.19 This research group
also demonstrated that LFU treatment may promote the
delivery of various topical solutions in the nasal cavity,
except for the frontal sinus.19
This preliminary study investigates the effective-
ness and microscopic safety of low-frequency continuous-
wave ultrasound treatment in biofilm disruption in
chronic rhinosinusitis with nasal polyposis between in
vitro conditions.
MATERIALS AND METHODS
Patients
A case-control experimental study was performed on nasal
polyp specimens obtained from patients with CRSwNPwho under-
went ESS at the Department of Otorhinolaryngology and Head
and Neck Surgery, University of Debrecen. Nasal polyps (n ¼ 20)
were collected between January 2012 and April 2012. The patient
group consisted of four males and six females (n ¼ 10, mean age,
51.3 years; range, 32–61 years) with the diagnosis of CRSwNP
confirmed by nasal endoscopy and computed tomography (CT)
scans of the paranasal sinuses. All the nasal polyps collected dur-
ing ESS were divided into two consecutive groups consisting of 10-
10 specimens that were processed to histopathological analysis
alone and LFU treatment, respectively. Only nasal polyps larger
than 2 cm were analyzed, which could be removed by straight en-
doscopic forceps without any surface injury or iatrogenic
disruption of biofilm layers. The removal was gently performed at
the root of the nasal polyps. All patients gave their informed con-
sent before donating their tissue samples for the study. The
institutional ethical committee approved our study. The study was
carried out according to the Declaration of Helsinki.
Hematoxylin–Eosin and Gram Staining
According to previous reports, a combination of hematoxy-
lin-eosin (HE) and Gram staining protocols seems to be a usable
method for the detection of biofilm existence and corresponding
histopathological changes, because HE staining is for the inves-
tigation of microscopic architecture, whereas Gram protocol
stains various microbial elements.21,22 The first series of 10
LFU-untreated nasal polyps were fixed in 10% (w/v) formalde-
hyde. Specimens were embedded in 15% (w/v) purified gelatin
(24 hours, 56C) and refixed in 4% (w/v) paraformaldehyde (24
hours, 20C). Blocks were cryoprotected in 20% (w/v) sucrose so-
lution (2 hours, 4C) and sectioned into 5-lm slides at 25C
(MNT-200; Slee, Mainz, Germany). Slides were stored in 0.1 M
phosphate-buffered saline containing 0.03% (w/v) sodium azide
at 4C. Two consecutive 5-lm frozen-cut sections were examined
as follows: 1) conventional staining with HE, and 2) conventional
Gram staining. The criteria for the histopathological detection of
microbial biofilms were the presence of characteristic morphol-
ogy and Gram positivity/negativity and microcolonies for
examination by optical microscopy and the presence of the sur-
rounding polysaccharide layer.22 Structure and cellular
infiltration of the epithelial and also the subepithelial layers
were correlated to the presence of bacterial biofilms.
In Vitro LFU Treatment
The second series of nasal polyps were placed into 0.9%
(w/v) sodium chloride solution immediately after surgical re-
moval. LFU treatment protocol was started within 30 minutes
after tissue sampling (Sonica 5200-EP; Soltec, Milan, Italy).
Nasal polyp specimens were placed into a self-designed silicone
vat. LFU treatment with 0.4 MHz frequency and 0.5 W/cm2
sound pressure was employed for 5 minutes at 37C in 20 mL
total volume of 0.9% (w/v) sodium chloride solution. A digital
thermometer was applied to register any temperature changes
during the protocol. Ultrasound-treated nasal polyps were fixed
in 10% (w/v) formaldehyde and then the same histopathological
staining protocols were performed that were previously
described. Histopathological characteristics of biofilms, and epi-
thelial and subepithelial layers of untreated specimens were
correlated to ultrasound-treated identical nasal polyp pairs with
the aim of analyzing the effects of therapeutic ultrasound on
biofilms and microscopic structures. Statistical assessments
were performed by Mann-Whitney U probe with a 95% confi-
dence interval (SPSS 9.0 for Windows; SPSS, Inc. Chicago, IL).
Histological pretreatment protocols were performed by an inde-
pendent laboratory assistant in all cases. Both sets of
histological examinations in the LFU-treated and untreated
sample groups were independently analyzed by two researchers
(P.C. and T.K.).
RESULTS
Altogether, 10 patients with CRSwNP who under-
went ESS were included in this study. The Lund-
Mackay scores of coronal reconstructed CT scans varied
between 15 and 24 with an average score of 21, indicat-
ing serious involvement of paranasal sinuses by CRS.
The score was higher than 21 in 70% of patients (n ¼ 7).
The clinical history and findings of physical examina-
tions were obtained during confirmation of the diagnosis
of CRSwNP. Clinical information on bronchial asthma,
allergic rhinitis, aspirin intolerance, previous ESS, topi-
cal steroid treatment, and systemic antimicrobial
therapy was recorded before surgery. Three patients
(30%) had bronchial asthma, 10% (n ¼ 1) had allergic
rhinitis, and 10% (n ¼ 1) had the diagnosis of aspirin
intolerance. This patient had complete acetylsalicylic
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acid triad (nasal polyposis, bronchial asthma, and aspi-
rin intolerance). Diagnosis of allergic rhinitis was based
on the clinical history, on the physical examination,
and on the allergen-specific intracutaneous (prick) skin
test. Inhalative allergen-specific serum immunoglobulin
G levels were also measured by enzyme-linked immu-
nosorbent assay in all cases. The diagnosis of bronchial
asthma was based on the clinical history and on the re-
spiratory functional test. The final diagnosis was stated
by an experienced pulmonologist in all cases. Aspirin
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Fig. 1. Microphotographs of nasal polyps stained by hematoxylin-eosin before and after low-frequency ultrasound treatment. (A1) At low
magnification, a columnar epithelium with eosinophilic polysaccharide layer can be detected (black arrow). The submucosal layer is marked
by a white arrow, whereas the black asterisk indicates the stromal layer with massive infiltration of inflammatory cells. (A2) Microbial biofilm
is displayed as a dense, eosinophilic structure on the surface of epithelial layer (black arrow). The white arrow shows the submucosa. (A3)
Stromal substance of the nasal polyp is heavily infiltrated by eosinophil and neutrophil granulocytes and also by plasmocytes. (B1) At low
magnification, a columnar epithelium without biofilm-like structures can be detected (black arrow). The submucosal layer is marked by a
white arrow, whereas black asterisk indicates the hypocellular stromal layer. (B2) The respiratory epithelium shows intact architecture
without any signs for superficial biofilm presence (black arrow). The white arrow shows the intact submucosal layer. (B3) The stromal layer
represents as a hypocellular structure with sporadic inflammatory cells and intact connective tissue web.
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intolerance was based on the presence of aspirin-
induced hypersensitive reactions in the clinical history
of the patients. Repeated ESS was performed in 50% (n
¼ 5) of patients, which is an important predictive fac-
tor of CRS recurrence. In this group, number of
previous surgeries varied between two to four, with an
average number of three ESSs. All patients were
treated by topical mometasone furoate monohydrate
(200 lg/day, Nasonex; Merck–Schering-Plough, White-
house Station, NJ) therapy before surgery. The average
period of intranasal steroid treatment was 22.8 months,
which varied between 11 to 63 months. Preoperative
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Fig. 2. Microphotographs of
Gram-stained nasal polyps
before and after low-frequency
ultrasound treatment. (A1) Gram
staining indicates a bacterial bio-
film consisting of several chains
of Gram-positive cocci (black
arrow). (A2) Higher magnification
view of the previous section. The
black arrow shows bacteria of
0.3 to 0.5 lm in size. (A3) Gram
staining reveals a bacterial bio-
film with intraepithelial invasion of
Gram-positive cocci (white
arrow). (A4) At higher magnifica-
tion, a serious intracellular bacte-
rial infiltration can be detected in
the epithelial layer (white arrow).
(B1) Gram staining is negative for
bacterial elements; the polysac-
charide matrix is absent (black
arrow). (B2) Higher magnification
view of the previous section. (B3)
The epithelial layer is intact; bio-
film cannot be detected (black
arrow). (B4) Higher magnification
view of the previous specimen.
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(within 6 weeks), systemic antibiotic treatment (cefur-
oxime) was performed in one (10%) patient due to
acute rhinosinusitis.
The histopathological examination revealed inflam-
matory nasal polyps with polymorphonuclear and
plasmocyte infiltration of the subepithelial layer in all
cases (Fig.F1 1). Disintegrated epithelial layer with partial
squamous cell metaplasia was found in seven cases (n ¼
7, 70%), whereas in three nasal polyps (n ¼ 3, 30%) the
epithelium showed normal architecture with ciliated co-
lumnar and foamy cells (Fig. 1). Bacterial biofilms were
detected in all patients with CRSwNP (Figs. 1 andF2 2, Ta-
bleT1 I). In our series, HE staining displayed a strong
correlation with the results of Gram staining and was
found to be a reliable predictor of the presence or ab-
sence of biofilms. In the LFU-untreated group, thickness
of biofilm layer varied between 9.24 to 22.53 lm, with
the average of 17.3 lm (Table I). In the LFU-treated
group of nasal polyps, combined application of HE and
Gram-staining protocols revealed the total absence of
bacterial biofilms (P < .001) (Figs. 1 and 2, Table I). In
the LFU-untreated nasal polyps, the stromal substance
displayed a serious inflammatory cell infiltration that
was predominantly formed by eosinophil and neutrophil
granulocytes (Fig. 1). In the average of 10 large magnifi-
cation microscopic fields, the inflammatory cell count
varied between 486 to 730.4, with the average of 603.72
cells (Fig. 1, Table I). In the LFU-treated group, the av-
erage number of inflammatory cells decreased to 38.81,
which was a statistically significant difference (P < .001)
(Fig. 1, Table I). Architectural changes due to LFU treat-
ment were not detected in the epithelial or in the
subepithelial layers of nasal polyps (Fig. 1). In the LFU-
treated group, the reticular pattern of the connective tis-
sue web remained intact, and no signs of vascular
damage, leukocyte disintegration, or karyorrhexis (leu-
kocytoclasia) could be detected (Fig. 1). No significant
temperature changes were detected during LFU treat-
ment (average DT was 0.34C).
DISCUSSION
In the present study, we demonstrated the presence
of biofilms in all patients with CRSwNP by the combined
application of HE and Gram protocols.22 The weakness
of our study is the absence of a control group and the
relatively low number of subjects, which should be
increased in the future to obtain more precise statistical
correlations. Although the presence of biofilm itself is
supposed to be an important factor in the pathogenesis
of CRSwNP, microbiological identification of different
bacterial and fungal species involved in biofilm forma-
tion still requires culturing, confocal laser scanning
microscopy, or fluorescent in situ hybridizations analysis
with species-specific oligonucleotide probes.4,23
The presence of microbial biofilms is suspected to
affect the intensity of subepithelial inflammatory reac-
tion in CRSwNP.6–8 Inflammatory cells accumulating in
the subepithelial and stromal layer of nasal polyps are
responsible for the uncontrolled release of several proin-
flammatory cytokines.8,9,13 Increased expression of IL-1,
tumor necrosis factor-a, receptor AQ2activator of nuclear fac-
tor kappa-B ligand, and macrophage colony-stimulating
factor may lead to epithelial disintegration and
increased connective tissue formation in the stromal
substance.7,9,13,14 Because biofilms might play a central
role in chronic inflammation and nasal polyp formation;
disruption of these microbial structures seems to be
essential in the nonsurgical treatment of CRSwNP.3,6,10
CUS or PUS low-frequency ultrasound treatment
has been reported as a potent therapeutic option for the
physical disruption of biofilms in CRSwNP.10,17,18 The
idea is not new and has physical evidence, because LFU
is widely used for the cleaning of laboratory devices with
superficial biofilm contamination.10 Therapeutic ultra-
sound of 0.4 to 3.3 MHz frequencies is commonly used in
the rheumatology practice and in rehabilitation medi-
cine. In soft tissues, maximum energy absorption varies
between 2 to 4 cm. Therapeutic ultrasound has various
tissue effects: it increases blood flow in the treated area,
decreases edematous swelling, and results in microcavi-
tation and acoustic streaming.19,20 Microcavitation
originates from the ultrasound-induced vibration of soft
tissues that results in the formation of microscopic air
bubbles, which transmit these vibrations directly to the
cell membranes, vascular walls, and to biofilms.17,18
According to our results, LFU treatment can be
supposed as a reliable and safe method for biofilm dis-
ruption in CRSwNP. It was found that the amount of
inflammatory cells in the subepithelial and stromal
layers showed a statistically significant decrease due to
LFU treatment. Ultrasound-induced movement, intra-
vascular microstreaming, and the escape effect of
leukocytes at the surgical resection surface of nasal pol-
yps might be responsible for this finding. At this point,
it seems to be an interesting observation; however, its
TABLE I.
Histological Parameters of Biofilm Thickness and Subepithelial Cellular Infiltration in Nasal Polyps According to
Low-Frequency Ultrasound Treatment.
Nasal Polyp Specimens (n ¼ 20) LFU-Untreated Group (n ¼ 10)* LFU-Treated Group (n ¼ 10) P Value†
Biofilm thickness (mm)‡ 17.3 (9.24–22.53) 0 (0) <.001
Inflammatory cell count in the stromal layer§ 603.72 (486–730.4) 38.81 (17.5–71.3) <.001
*Low-frequency ultrasound (LFU) treatment between in vitro conditions (5 minutes, 37C, 0.4 MHz).
†P value at 95% confidence interval (Mann-Whitney U probe).
‡Mean value of biofilm thickness in the average of 10 large magnification microscopic fields (range).
§Mean value of inflammatory cell number (lymphocyte, plasmocyte, neutrophil, basophil, and eosinophil granulocyte) in the average of 10 large magnifi-
cation microscopic fields (range).
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clinical effects are unpredictable. This unclarified phe-
nomenon may have beneficial effects in the treatment of
CRSwNP by a significant reduction of subepithelial
inflammation in the nasal mucosa. On the other hand,
an uncontrolled release of inflammatory cytokines and
consecutive inflammatory reactions with serious rebound
effects are also conceivable. Although no leukocyte
destruction was found, the answer requires further
research between controlled clinical conditions.
According to enhanced wave reflection at tissue bor-
ders and limited penetration depth, extranasal
application of LFU protocol seems to be only a sympto-
matic treatment in CRSwNP.18 In the near future,
intranasal application of LFU treatment will need to be
tested in biofilm disruption in CRSwNP (Fig.F3 3). To
avoid sound reflection that occurs at air interfaces in the
nasal cavity, a transducing medium is necessary for the
ultrasound energy to be delivered to the mucosal surfa-
ces. We do think that after intranasal upload of 0.9%
(w/v) sodium chloride solution, application of a thin and
special low-frequency ultrasound probe with potential
temperature and sound pressure control will be a reli-
able method in the nonsurgical treatment of CRSwNP
(Fig. 3). Certainly, this hypothesis requires several fur-
ther research and clinical studies in the future.
Corticosteroids have beneficial effects on the symp-
toms of CRSwNP and significantly decrease nasal
obstruction and olfactory dysfunction.1,2,13 On the other
hand, steroid treatment may have adverse effects on bio-
film presence due to the inhibition of local immune
response.13,22 As we have concluded previously, steroid
and systemic antibiotic treatment might adversely affect
the structure and thickness of biofilms.22 However, a
combination of topical steroid medication, systemic anti-
biotic treatment, and LFU protocol may have additional
beneficial effects in the nonsurgical treatment of
CRSwNP. In the future, placebo-controlled, double-
blinded, multicenter studies will be necessary to prove
the effectiveness of this combination of different thera-
peutic protocols.
CONCLUSION
This study indicates a potential therapeutic effect of
LFU treatment in CRSwNP, because bacterial biofilms
were completely removed in the LFU-treated group of
nasal polyps. In general, therapeutic considerations can
be divided into two main groups: blockade of biofilm for-
mation and eradication of biofilms that have already
formed (Fig. 3). Although specific treatments are not yet
available to target microbial biofilm, its detection and
eradication is an important requirement, because it is
strongly associated with treatment failures and persist-
ing symptoms of CRSwNP. In the future, systemic
double-blinded studies will be required to confirm the
therapeutic effectiveness of the LFU-protocol in the non-
surgical treatment of CRSwNP.
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